Munich Reinsurance Co Stock Corp in Munich Sells 2,916 Shares of Amgen Inc. $AMGN

Posted by Brenda Bartman on Jul 10th, 2026

Munich Reinsurance Co Stock Corp in Munich cut its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 83.8% during the first quarter, HoldingsChannel reports. The firm owned 563 shares of the medical research company’s stock after selling 2,916 shares during the period. Munich Reinsurance Co Stock Corp in Munich’s holdings in Amgen were worth $198,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. High Note Wealth LLC grew its stake in Amgen by 5.8% in the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after acquiring an additional 28 shares in the last quarter. TAGStone Capital Inc. raised its stake in shares of Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares in the last quarter. Verus Capital Partners LLC raised its stake in shares of Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares in the last quarter. Destination Wealth Management raised its stake in shares of Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares in the last quarter. Finally, Breakwater Capital Group boosted its holdings in shares of Amgen by 1.4% in the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after purchasing an additional 29 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 1.2%

Shares of NASDAQ:AMGN opened at $363.62 on Friday. The company has a market capitalization of $196.25 billion, a PE ratio of 25.30, a P/E/G ratio of 3.63 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29. The business’s fifty day simple moving average is $344.30 and its 200-day simple moving average is $349.22.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the business posted $4.90 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts predict that Amgen Inc. will post 22.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wells Fargo & Company increased their price objective on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. BMO Capital Markets reiterated an “outperform” rating and issued a $400.00 target price on shares of Amgen in a report on Wednesday, July 1st. Mizuho increased their price target on Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 16th. Truist Financial raised their price target on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research note on Tuesday. Finally, UBS Group lifted their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $355.73.

Get Our Latest Report on AMGN

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.